Últimas noticias sobre Nippon Steel (OTC:NPSCY) Bolsa

Nippon Steel Corporation, or NS, is the largest steel producer in Japan and one of the top five producers globally. NS supplies steel products such as steel sheets, steel plates, pipes, tubes, bars, wire rods, and stainless steels. It is mainly exposed to the auto, construction, and energy sectors. Steelmaking accounts for around 85%-90% of its revenue, while the remainder stems from engineering and construction, chemicals, new materials, and system solutions. Around 35%-40% of its revenue is from exports.

News

Commodities

Movers

Media

Trading Ideas

NPSCY

Joe Biden bloquea la adquisición de U.S. Steel por Nippon Steel, citando preocupaciones de seguridad nacional y defensa de la industria local.

Biden bloquea la compra de U.S. Steel por Nippon Steel: Seguridad nacional en juego

NIPPON STEEL CORP S/ADR by Nippon Steel Corporation

Nippon Steel Corp

JP Morgan analyst Daniel Politzer initiates coverage on MGM Resorts International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MGM#NYSE">MGM</a>) with a Neutral rating and announces Price Target of $38.

Price Target

Initiation

Analyst Ratings

JP Morgan Initiates Coverage On MGM Resorts International with Neutral Rating, Announces Price Target of $38

<a href="https://www.globenewswire.com/Tracker?data=XirGA5aw79jfnb954sJ8SO-QlmTWEPUdfHRnU_c8XfLyv01hCB7R-79L-P0cPcb74skAsYHKmOo7MY6GZHTfwxcPr0jZKblewWWMGUcTL70=">SharpLink Gaming, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBET#NASDAQ">SBET</a>) ("SharpLink" or the "Company"), the largest publicly traded holder of ETH in the world, today announced that the Company's common stock has been approved for options trading on the Nasdaq Options Market ("Nasdaq").
Options trading on SharpLink will be available through the Options Clearing Corporation ("OCC"), and will be subject to standard rules and regulations established by Nasdaq and the OCC.

SBET

SharpLink Gaming Common Stock Approved For Options Trading On Nasdaq Options Market

Goldman Sachs analyst Leah Jordan initiates coverage on Pilgrims Pride (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PPC#NASDAQ">PPC</a>) with a Neutral rating and announces Price Target of $50.

Goldman Sachs Initiates Coverage On Pilgrims Pride with Neutral Rating, Announces Price Target of $50

<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="900" height="600" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/23080959/Allystarjpg.jpeg" alt="" class="wp-image-14738" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/23080959/Allystarjpg.jpeg 900w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/23080959/Allystarjpg-300x200.jpeg 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/23080959/Allystarjpg-768x512.jpeg 768w" sizes="(max-width: 900px) 100vw, 900px" /></figure>
The satellite positioning chip designer previously planned to float shares on China's domestic A-share market, but has shifted its sights to Hong Kong with its new listing application 
<h4 class="wp-block-heading">Key Takeaways:</h4>
<ul class="wp-block-list">
<li>Hong Kong IPO applicant Allystar Technology continues to report losses, but could soon become profitable as it achieves economies of scale and other greater efficiencies</li>
<li>The company has signed strategic partnerships with many big tech names such as Meituan, BYD and ZTE</li>
</ul>
The rise of location-based apps and smart cities, combined with a new dawn of the internet of everything (IoE), has created strong demand for positioning services that are putting&nbsp;Allystar Technology (Shenzhen) Co. Ltd.&nbsp;on the investor map. Now, the leading positioning chip designer is trying to cash in on its rising star with a recent application to list in Hong Kong.
The company has done some directional shifting of its own, moving its sights to the more internationally focused Hong Kong after originally planning to chase a listing on China's domestic A-share market.
Allystar uses navigation chip technology and an R&amp;D team it acquired in 2017 from&nbsp;Huada Technology&nbsp;(0085.HK), a subsidiary of state-run electronics giant China Electronics Corp. (CEC), a year after its founding by seven shareholders, according to its listing document filed earlier this month. It began mass producing its dual-frequency high-precision navigation and positioning system-on-chips (SoC) in 2019 for use in the BeiDou system, China's homegrown alternative to the globally popular U.S.-based GPS. Since then, it has also begun making chips for use in other major global positioning systems, including GPS.
Allystar's current shareholding is quite diverse, with no single company holding more than 10% of its stock. Its largest shareholder is CEC subsidiary China Electronics Optics Valley Union (0798.HK), which holds a 9.2%. Other shareholders include China Citic Bank and China Merchants Bank, with 7.2% and 7.1% stakes, respectively. New energy vehicle and battery giant BYD (1211.HK; 002594.SZ) is also an early investor with 4.1%, while fellow carmaker SAIC Motor holds 1.8% through a joint venture. Robert Bosch Venture Capital, an investment arm of German automotive parts giant Bosch, also holds 2.95%.
<h4 class="wp-block-heading">Sixth-largest global positioning chip supplier</h4>
Global navigation satellite systems provide positioning, navigation, and timing services via satellites and chips, and are used to help apps determine global positioning. Four such systems are currently operating worldwide, including China's BeiDou, the U.S. GPS, Russia's Glonass and the EU's Galileo.
Allystar's SoC products are ultra-low in power consumption and use AI-integrated positioning algorithms. The company uses an asset-light model of designing its chips and manufacturing them using third-party foundries. It is the sixth-largest such chipmaker globally with 4.8% of the market, and the second largest in China, based on its units shipped.
The global positioning services market is growing rapidly, worth about 2 trillion yuan ($278 billion) in 2023 alone, driven by development of mobile internet and internet of things (IoT) technologies. Rapid AI advancements fueling a new wave of increasingly sophisticated consumer electronics, along with rapid growth in automotive intelligence and the low-altitude economy, are expected to keep the market growing by 9.1% annually to reach 3.25 trillion yuan by 2028, according to third-party market data in Allystar's listing document.
<h4 class="wp-block-heading">Sales, R&amp;D spending drag</h4>
Allystar's revenue comes from two main segments: global navigation chips, modules, and related solutions; and high-precision chips and modules. Last year, those two accounted for 28.3% and 71.7% of its revenue. Global navigation chips contributed 238 million yuan and high precision chips provided 602 million yuan, bringing the total to 840 million yuan, up 30.2% year-on-year.
It's worth noting that while the high-precision chip and module business is the company's biggest breadwinner, that segment's gross margin was extremely low at just 2.8% last year. By comparison, the smaller global navigation segment had lower revenue but a much higher gross margin of 27.3%. As a result, global navigation chips contributed 65 million yuan of Allystar's gross profit last year, much higher than the 17 million yuan provided by the high-precision chips and modules business. The company's total gross profit of 82 million yuan last year was also up by 20.7% from 2023.
Despite the strong revenue and gross profit growth, the company still reported a loss of 141 million yuan last year due to significant sales and R&amp;D costs. That said, the loss still narrowed by roughly half from 2023.
Allystar believes it can continue to stem the flow of red ink and become profitable, stating it plans to reach such a goal in the near future by improving its gross margin, enhancing its operational efficiency and optimizing its working capital management. The company points out it expects its gross margin to significantly improve as companies roll out increasingly sophisticated global positioning products and solutions, and that such growing demand will also help it to reach greater economies of scale.
<h4 class="wp-block-heading">Fragmented shareholding</h4>
Allystar's client portfolio looks quite strong, featuring strategic tie-ups with the likes of takeout dining giant Meituan, bike-sharing operators Hello Inc. and DiDi Bike, smart vehicle technology companies BYD, ZTE and SAIC Motor, and telecoms carriers China Mobile and China Unicom in the smart cities space.
Hong Kong-listed chip designers are doing well in general lately, which could help to boost sentiment towards Allystar's offering. Among those,&nbsp;Horizon Robotics&nbsp;(9660.HK) and&nbsp;Black Sesame&nbsp;(2533.HK) current trade at healthy price-to-sales (P/S) ratios of 12 times and 9 times, respectively. Allystar's 840 million yuan in revenue last year and a similar P/S ratios of 7 times to 8 times would value the company at about 6.3 billion yuan, near unicorn status defined as a market value of more than $1 billion.
But one key concern could be Allystar's highly fragmented shareholding structure. Its largest stakeholder owns less than 10% of its shares, while as many as 42 hold less than 3%, and 21 hold less than 1%. Many of those smaller holders are quite likely to sell their stakes after the company's lock-up period expires, which could create some volatility for the stock as the company tries to position in the global investor constellation.

Asia

IPOs

Opinion

Fragmented Shareholding Positions Allystar For Turbulence

B of A Securities analyst Adrien de Saint Hilaire upgrades Omnicom Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OMC#NYSE">OMC</a>) from Underperform to Neutral and maintains the price target from $80 to $80.

Upgrades

B of A Securities Upgrades Omnicom Group to Neutral, Maintains Price Target to $80

A <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4453724-1&amp;h=1831616177&amp;u=https%3A%2F%2Fwww.leidos.com%2F&amp;a=Leidos">Leidos</a>-led (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LDOS#NYSE">LDOS</a>) modernization initiative, involving companies from France, Germany, Italy, and the U.K., aims to enhance NATO's IT infrastructure. The project is designed to improve resilience against cyber threats and increase efficiency and scalability, in support of NATO digital transformation.
Leidos was awarded a contract from the NATO Communications and Information Agency (NCIA) for the provision of a centralized IT solution (based on private cloud technology) to support NATO's operational network, integrating core services such as service management and cybersecurity with the goal of enhancing interoperability and operational efficiency across the NATO command structure.
"This project reflects our long-standing commitment to NATO, leveraging innovative solutions aimed at delivering secure, mission-ready capabilities designed to adapt with operational needs," said Steve Hull,&nbsp;Leidos&nbsp;digital modernization sector president. "It also creates new opportunities for more integrated collaboration across trans-Atlantic defense networks, helping NATO teams stay securely connected and able to share critical information with greater speed, agility and assurance."
Thales (France), CGI (Germany), Leonardo (Italy), LA International (U.K.) and NEXOR (U.K.) are joining Leidos as a multi-national team with extensive knowledge of NATO requirements and a strong track record of delivering results. Collectively, they have supported NATO's work for decades.
The IT Modernization Recovery Increment 1 Systems Integration contract bolsters Leidos' role as a key technology partner with NCIA, supporting NATO's mission and advancing secure cloud modernization. It has a ceiling value of $87 million (€79.1 million) on indefinite delivery indefinite quantity (IDIQ) firm-fixed price terms. &nbsp;

Contracts

LDOS

Leidos Announces It Was Awarded A Contract From The NATO Communications And Information Agency

<h3>Gainers</h3>
<ul>
<li>Wag Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PET#NASDAQ">PET</a>) shares moved upwards by 16.7% to $0.11 during Monday's pre-market session. The market value of their outstanding shares is at $4.7 million. </li>
<li>Birks Group (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/BGI#AMEX">BGI</a>) shares rose 13.92% to $1.04. The market value of their outstanding shares is at $17.5 million. </li>
<li>Xcel Brands (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XELB#NASDAQ">XELB</a>) shares rose 8.6% to $2.02. The company's market cap stands at $4.4 million. </li>
<li>Interactive Strength (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRNR#NASDAQ">TRNR</a>) stock moved upwards by 7.26% to $0.74. The company's market cap stands at $6.9 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>FST (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KBSX#NASDAQ">KBSX</a>) shares fell 13.8% to $1.81 during Monday's pre-market session. The company's market cap stands at $94.0 million. </li>
<li>Jeffs Brands (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JFBR#NASDAQ">JFBR</a>) stock fell 12.56% to $6.55. The market value of their outstanding shares is at $4.1 million. </li>
<li>Netclass Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTCL#NASDAQ">NTCL</a>) stock fell 9.43% to $1.63. The market value of their outstanding shares is at $32.0 million. </li>
<li>Genius Group (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/GNS#AMEX">GNS</a>) stock fell 6.69% to $0.51. The company's market cap stands at $39.0 million. </li>
<li>Fitell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTEL#NASDAQ">FTEL</a>) shares declined by 6.27% to $0.46. The company's market cap stands at $9.9 million. </li>
<li>SharpLink Gaming (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBET#NASDAQ">SBET</a>) stock declined by 6.1% to $9.25. The market value of their outstanding shares is at $601.0 million. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

FTEL

JFBR

KBSX

NTCL

TRNR

XELB

10 Consumer Discretionary Stocks Moving In Monday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Indaptus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INDP#NASDAQ">INDP</a>) stock increased by 141.3% to $0.65 during Monday's pre-market session. The market value of their outstanding shares is at $4.3 million. </li>
<li>Impact BioMedical (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IBO#AMEX">IBO</a>) shares moved upwards by 104.55% to $0.74. The company's market cap stands at $4.3 million. </li>
<li>Cidara Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDTX#NASDAQ">CDTX</a>) shares moved upwards by 66.84% to $35.07. The company's market cap stands at $272.6 million. </li>
<li>Forte Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FBRX#NASDAQ">FBRX</a>) stock moved upwards by 40.78% to $20.64. The company's market cap stands at $96.5 million. </li>
<li>CARISMA Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CARM#NASDAQ">CARM</a>) shares moved upwards by 33.18% to $0.59. The market value of their outstanding shares is at $18.4 million. </li>
<li>Exelixis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) stock increased by 23.13% to $49.71. The market value of their outstanding shares is at $11.0 billion. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Compass Pathways (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMPS#NASDAQ">CMPS</a>) shares declined by 35.2% to $3.0 during Monday's pre-market session. The company's market cap stands at $433.1 million. </li>
<li>SS Innovations (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SSII#NASDAQ">SSII</a>) shares declined by 21.39% to $5.44. The company's market cap stands at $1.3 billion. </li>
<li>Alaunos Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCRT#NASDAQ">TCRT</a>) shares decreased by 18.19% to $3.51. The market value of their outstanding shares is at $7.0 million. </li>
<li>Hims &amp; Hers Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) shares fell 17.13% to $53.22. The market value of their outstanding shares is at $14.3 billion. </li>
<li>Processa Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCSA#NASDAQ">PCSA</a>) shares fell 15.13% to $0.27. The company's market cap stands at $3.8 million. </li>
<li>Innovative Eyewear (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUCY#NASDAQ">LUCY</a>) shares decreased by 13.32% to $3.06. The market value of their outstanding shares is at $10.9 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CARM

CDTX

CMPS

EXEL

FBRX

Hims & Hers Health, Inc. Class A Common Stock

HIMS

INDP

LUCY

PCSA

SSII

TCRT

12 Health Care Stocks Moving In Monday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>OceanPal (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OP#NASDAQ">OP</a>) stock rose 56.9% to $2.26 during Monday's pre-market session. The company's market cap stands at $10.8 million. </li>
<li>Robin Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RBNE#NASDAQ">RBNE</a>) shares moved upwards by 28.41% to $7.86. The company's market cap stands at $14.6 million. </li>
<li>Huachen AI Parking Mgmt (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCAI#NASDAQ">HCAI</a>) shares moved upwards by 22.18% to $1.2. The company's market cap stands at $33.1 million. </li>
<li>Aqua Metals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AQMS#NASDAQ">AQMS</a>) stock rose 14.47% to $0.72. The market value of their outstanding shares is at $5.6 million. </li>
<li>Energy Focus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EFOI#NASDAQ">EFOI</a>) shares moved upwards by 13.85% to $1.89. The company's market cap stands at $8.9 million. </li>
<li>SU Group Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SUGP#NASDAQ">SUGP</a>) shares rose 13.57% to $0.52. The market value of their outstanding shares is at $6.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Dragonfly Energy Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DFLI#NASDAQ">DFLI</a>) shares declined by 21.4% to $0.2 during Monday's pre-market session. The company's market cap stands at $2.3 million. </li>
<li>Ryde Group (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/RYDE#AMEX">RYDE</a>) shares fell 15.14% to $0.34. The company's market cap stands at $11.6 million. </li>
<li>Solidion Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STI#NASDAQ">STI</a>) stock fell 12.27% to $3.29. The company's market cap stands at $10.1 million. </li>
<li>Nephros (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEPH#NASDAQ">NEPH</a>) stock fell 12.0% to $4.4. The market value of their outstanding shares is at $53.0 million. </li>
<li>Erayak Power Solution Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RAYA#NASDAQ">RAYA</a>) stock decreased by 10.72% to $2.0. The company's market cap stands at $100.8 million. </li>
<li>CDT Envirn Tech Inv Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDTG#NASDAQ">CDTG</a>) shares declined by 10.71% to $0.75. The market value of their outstanding shares is at $10.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AQMS

CDTG

DFLI

EFOI

HCAI

NEPH

RAYA

RBNE

RYDE

SUGP

12 Industrials Stocks Moving In Monday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Sequans Communications (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SQNS#NYSE">SQNS</a>) shares rose 19.2% to $2.3 during Monday's pre-market session. The market value of their outstanding shares is at $119.5 million. </li>
<li>Zeta Global Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZETA#NYSE">ZETA</a>) stock rose 17.63% to $16.68. The market value of their outstanding shares is at $3.3 billion. </li>
<li>SemiLEDs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LEDS#NASDAQ">LEDS</a>) stock moved upwards by 16.73% to $3.0. The market value of their outstanding shares is at $18.5 million. </li>
<li>Datavault AI (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DVLT#NASDAQ">DVLT</a>) stock rose 12.58% to $0.68. The company's market cap stands at $39.8 million. </li>
<li>Airship AI Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AISP#NASDAQ">AISP</a>) shares increased by 8.39% to $5.68. The company's market cap stands at $166.8 million. </li>
<li>Signing Day Sports (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SGN#AMEX">SGN</a>) stock rose 7.58% to $1.13. The company's market cap stands at $3.8 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Next Technology Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXTT#NASDAQ">NXTT</a>) stock decreased by 29.9% to $2.41 during Monday's pre-market session. The market value of their outstanding shares is at $1.5 billion. </li>
<li>Marin Software (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRIN#NASDAQ">MRIN</a>) shares decreased by 15.27% to $1.11. The market value of their outstanding shares is at $4.1 million. </li>
<li>Wolfspeed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WOLF#NYSE">WOLF</a>) stock fell 13.35% to $0.78. The market value of their outstanding shares is at $140.0 million. </li>
<li>Sonim Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SONM#NASDAQ">SONM</a>) stock decreased by 11.03% to $1.13. The market value of their outstanding shares is at $13.0 million. </li>
<li>Auddia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AUUD#NASDAQ">AUUD</a>) stock declined by 8.12% to $4.3. The market value of their outstanding shares is at $2.9 million. </li>
<li>Blaize Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BZAI#NASDAQ">BZAI</a>) shares decreased by 5.91% to $2.55. The market value of their outstanding shares is at $275.5 million. 
See Also: <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AISP

AUUD

BZAI

DVLT

LEDS

MRIN

Next Technology Holding Inc. - Ordinary Shares

NXTT

SONM

SQNS

WOLF

ZETA

12 Information Technology Stocks Moving In Monday's Pre-Market Session

Emergent BioSolutions Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>) today announced it has been awarded a $62.4 million contract modification from the Administration for Strategic Preparedness and Response (ASPR), a division of the&nbsp;United States Department of Health and Human Services&nbsp;(HHS) for BAT&#xAE; [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)]. The modification has been made to the existing 10-year contract with ASPR (75A50119C00075) whereby Emergent will supply BAT&#xAE;, an antitoxin used in the treatment of symptomatic botulism following suspected or confirmed exposure to botulinum neurotoxin serotypes A, B, C, D, E, F, or G in both adults and pediatric patients.

Emergent Biosolutions Bags $62.4M Contract Modification From United States Department Of HHS' ASPR For BAT

JMP Securities analyst Silvan Tuerkcan maintains Exelixis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) with a Market Outperform and raises the price target from $47 to $50.

JMP Securities Maintains Market Outperform on Exelixis, Raises Price Target to $50

Carisma Therapeutics Shares Resume Trade

JP Morgan analyst Daniel Politzer initiates coverage on Las Vegas Sands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LVS#NYSE">LVS</a>) with a Neutral rating and announces Price Target of $47.

JP Morgan Initiates Coverage On Las Vegas Sands with Neutral Rating, Announces Price Target of $47

Management

CADL

Candel Therapeutics Appoints Charles Schoch As CFO, Effective Immediately

Health Care

General

Novo Nordisk Says Direct Access To Wegovy Will No Longer Be Available To Hims & Hers Health Via NovoCare Pharmacy

<ul>
<li>Initial pharmacological data from placebo-controlled, double-blind Phase I study shows significant T cell suppression and a favourable safety profile at dosing level of 0.9 mg/kg</li>
<li>The substantial reduction in T cell activity highlights the potential efficacy of IMP761 in treating autoimmune diseases</li>
<li>Single ascending dose levels will continue with 2.5, 7 and 14 mg/kg</li>
<li>Additional data from the Phase I to follow in second half of CY2025</li>
</ul>
&nbsp;SYDNEY, AUSTRALIA, June 23, 2025 (GLOBE NEWSWIRE) --&nbsp; <a href="https://www.globenewswire.com/Tracker?data=85DL1Pt7SAoXPlQKyegR46K4jRcbw4sp20YqC0mm773uq-1JJcab9hwIG6oq2yNoCoG6fsL9sfo7pVqvXgV0UQ==">Immutep Limited</a> ((ASX: IMM, NASDAQ:<a href="https://www.benzinga.com/stock/IMMP#NASDAQ">IMMP</a>) ("Immutep" or "the Company"), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces positive initial efficacy data and continued favourable safety data from the placebo-controlled, double-blind first-in-human Phase I study evaluating IMP761, a first-in-class LAG-3 agonist antibody for autoimmune diseases.
Through the highest dosing level to date (0.9 mg/kg of IMP761), there have been no treatment-related adverse events in healthy participants. Additionally, pharmacodynamic data at this dosing level show that the inhibition of T cell infiltration in the skin at day 10 following a neoantigen rechallenge has already reached 80%. Given the encouraging efficacy and safety, Immutep is continuing with single ascending dose levels of 2.5, 7 and 14 mg/kg.
The LAG-3 (lymphocyte-activation gene-3) immune checkpoint has been identified as a promising therapeutic target for rheumatoid arthritis, Type 1 diabetes, and multiple sclerosis in multiple publications.1-3&nbsp; IMP761 is the first LAG-3 agonist antibody developed to potentially treat these large and growing disorders, each of which represent multi-billion dollar markets, and many other autoimmune diseases. By enhancing the "brake" function of LAG-3 to silence dysregulated self-antigen-specific memory T cells, IMP761 is designed to target the cause of autoimmune diseases and restore balance to the immune system.

IMMP

Immutep Announces Initial Efficacy Data And Continued Safety Data From Placebo-Controlled, Double-Blind First-In-Human Phase I Study Evaluating IMP761, LAG-3 Agonist Antibody For Autoimmune Diseases

<a href="https://www.globenewswire.com/Tracker?data=ltX35oLa-RKtTY0lYnw3y9ujwfbOapgJiCLjI7xsx35MmXxJIwSRdkpth59LaT7BT9EnvYHHvxL9aDrHvHkopp54v6panamk65A1yeY-Nwk=">Oxbridge Re Holdings Limited</a> (Nasdaq: <a href="https://www.globenewswire.com/Tracker?data=ENhA7w6ThtAVn3AmoUgDNQ63BLUq3hHuAinMHd0yblHmLeJskIxrgTsF26NEauCPKAiU8yAr2j0cunbP8iV__X_KLDCi8f3sAHlblirxDc8=">OXBR</a>) ("Oxbridge Re"), a leader in digitizing reinsurance securities as tokenized real-world assets (RWAs), together with its subsidiary <a href="https://www.globenewswire.com/Tracker?data=1thrijpNL2o8psKrtI6ATAVgAJ1s1WHs70n7KqDa0iDXDhLAs4C3RHYfqy98Kp4BODFR41E3yjtWHtHwBYBLNg==">SurancePlus</a>, today announced an update to its previously announced strategic business review to maximize shareholder value.
The Company is actively reviewing a range of strategic initiatives for the company or its Web3 subsidiary, <a href="https://www.globenewswire.com/Tracker?data=1thrijpNL2o8psKrtI6ATJB6Q1qjlJuow0iVn4ajnYvA2I_x7YHb5p8oATTkThBsnLv_XZx-QdnRyRTM0N_7sTnCDZcPMzCa7T3wjp1Ui9E=">SurancePlus Holdings</a>—including a potential carve-out and Nasdaq listing of <a href="https://www.globenewswire.com/Tracker?data=1thrijpNL2o8psKrtI6ATJB6Q1qjlJuow0iVn4ajnYskizYwR38BYW6M6NljDQ-CjMKywpQcu-1CMgj9LLckZ4UijFjvGugaI-f8nsgiRhY=">SurancePlus Holdings</a>, as well as a potential financing transactions to support a digital asset treasury initiative and explore related M&amp;A opportunities.

OXBR

Oxbridge And Its Subsidiary SurancePlus Commences Strategic Review Of SurancePlus Carve Out And Potential Digital Asset Treasury Initiative

$70 Million ARR Locked in via Customer Contracts Microsoft and Google Partnerships Accelerate Momentum
&nbsp;Rezolve Ai (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RZLV#NASDAQ">RZLV</a>), the company reinventing retail through real-time AI-driven consumer engagement, today announced its inclusion in the prestigious Russell 2000&#xAE; and Russell 3000&#xAE; Indices, effective after market close on June 27, 2025, following the annual reconstitution by FTSE Russell.
The milestone reinforces a strong year for Rezolve Ai, which has surged from a standing start to $70 million in annual recurring revenue (ARR), months ahead of forecast, and is now on track to surpass $100 million ARR by year-end. We believe the Company's inclusion in the Russell indices reflects rapidly growing investor recognition of its transformative AI solutions and expanding global footprint.
"Joining the Russell indices is more than a symbolic milestone, it's a strong signal that the market is taking notice as we've gone from zero to $70 million ARR in less than two quarters," said Daniel M. Wagner, Chairman and CEO of Rezolve Ai. "The strategic alliances we have forged with Microsoft and Google are laying the foundation to accelerate revenue growth and position Rezolve as a leading global enterprise solution in AI-powered commerce. While we're excited about the momentum we've experienced to date, we believe we're just getting started."
Rezolve Ai's recent announcements include:
<ul>
<li>$70 million ARR milestone hit ahead of schedule, signaling surging enterprise adoption across global retail, logistics, and financial services.</li>
<li>Partnerships with Microsoft and Google, integrating Resolve's brainpowa LLM into Azure and expanding reach via Google Cloud Marketplace.</li>
</ul>
Inclusion in the Russell indices, benchmarks used by over $10.6 trillion in institutional assets, will increase Rezolve Ai's visibility among global investors and positions the Company for continued acceleration.

RZLV

Rezolve Ai Announces It Will Join Russell 2000 And Russell 3000 Indices

JP Morgan analyst Daniel Politzer initiates coverage on DraftKings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DKNG#NASDAQ">DKNG</a>) with a Overweight rating and announces Price Target of $50.

Comments

Nippon Steel

Noticias

Últimas noticias sobre Nippon Steel (OTC:NPSCY) Bolsa

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL